Posted on 20/10/2008 in Medical Company Product News Ark Therapeutics has announced that reimbursement approval has been secured from the NSH Business Services Authority for its KerraMax dressing for the management of leg ulcers.
The company intends to launch the product on November 1st, following listing in the NHS Drug Tariff.
KarrMax is a super-absorbent primary dressing designed for use in the management of moderate to heavy exudate in leg ulcers of venous etiology, the firm states, adding it has particularly application capacity for use under mild to moderate compression bandaging.
Commenting on the announcement, Cecile Miles, commercial director at Ark, states chronic leg ulcers are a problem affecting thousands of patients, as well as being costly and difficult to manage.
"KerraMax is an excellent product, offering significant absorbency benefits in dealing with exudate and we believe that it will bring significant benefits to patients suffering from leg ulcers and to the nurses who treat them," he continues.
Chief executive of Ark, Dr Nigel Parker, adds the firm is "very pleased" to announce the reimbursement approval of the treatment, as well as its planned launch next month.
"This product will be the second woundcare product launched by Ark since the summer, complementing our existing range of products," he notes.
Earlier this month, Ark announced reimbursement for Neuropad, a diagnostic test for early-stage peripheral autonomic neuropathy in the feet of diabetic patientsOther news stories from 20/10/2008
Read more in the Zenopa News Archive
How this news is generated
|
